Next Article in Journal
Two Point Mutations in the Glycoprotein of SFTSV Enhance the Propagation Recombinant Vesicular Stomatitis Virus Vectors at Assembly Step
Previous Article in Journal
B and T Cell Epitopes of the Incursionary Foot-and-Mouth Disease Virus Serotype SAT2 for Vaccine Development
Previous Article in Special Issue
Norovirus: An Overview of Virology and Preventative Measures
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 15
Issue 3
10.3390/v15030798
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Elucidating the Implications of Norovirus N- and O-Glycosylation, O-GlcNAcylation, and Phosphorylation

by
Chia-Chi Cheng
1,†,
Guan-Ming Ke
2,†,
Pei-Yu Chu
1,* and
Liang-Yin Ke
1,2,3,4,*
1
Department of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung 807378, Taiwan
2
Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 912301, Taiwan
3
Center for Lipid Biosciences, Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan
4
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Viruses 2023, 15(3), 798; https://doi.org/10.3390/v15030798
Submission received: 16 February 2023 / Revised: 19 March 2023 / Accepted: 21 March 2023 / Published: 21 March 2023
(This article belongs to the Special Issue Norovirus and Foodborne Diseases)
Browse Figures
Versions Notes

Abstract

:
Norovirus is the most common cause of foodborne gastroenteritis, affecting millions of people worldwide annually. Among the ten genotypes (GI–GX) of norovirus, only GI, GII, GIV, GVIII, and GIX infect humans. Some genotypes reportedly exhibit post-translational modifications (PTMs), including N- and O-glycosylation, O-GlcNAcylation, and phosphorylation, in their viral antigens. PTMs have been linked to increased viral genome replication, viral particle release, and virulence. Owing to breakthroughs in mass spectrometry (MS) technologies, more PTMs have been discovered in recent years and have contributed significantly to preventing and treating infectious diseases. However, the mechanisms by which PTMs act on noroviruses remain poorly understood. In this section, we outline the current knowledge of the three common types of PTM and investigate their impact on norovirus pathogenesis. Moreover, we summarize the strategies and techniques for the identification of PTMs.

1. Introduction

The most prevalent causes of foodborne outbreaks are noroviruses, which account for approximately 50% of all occurrences worldwide [1]. They cause 20% of all gastrointestinal illnesses worldwide, resulting in 200,000 deaths and 700 million infections annually [2,3]. Norovirus infections are characterized by emesis, acute watery diarrhea, nausea, low-grade fever, and abdominal cramps. Norovirus infections are usually transient, with symptoms vanishing within 12–72 h [4]. Although norovirus-associated disease is usually self-limiting, exposure to norovirus leaves neonates, the elderly, and immunocompromised patients vulnerable to chronic severe or life-threatening symptoms [5,6]. Norovirus infections are common among people of all ages and cause substantial health and economic burdens in developed and developing countries [6].
Noroviruses are single-stranded positive-sense ribonucleic acid (RNA) viruses that belong to the Caliciviridae family. Genomic RNA is covalently coupled to a viral protein (VPg) at the 5′ end and polyadenylated at the 3′ end [7]. Most norovirus genomes are structured into three open reading frames (ORFs), whereas murine noroviruses have four ORFs [8]. ORF1 encodes nonstructural proteins NS1/2 to NS7. Among these, NS7, an RNA-dependent RNA polymerase (RdRp), plays a crucial role in genome replication. ORF2 encodes the major capsid (VP1), which has a shell (S) and protruding (P) domain. The P domain can be divided into P1 and P2 subdomains. P2 can recognize human histo-blood group antigens (HBGAs), which are essential for receptor binding [9,10,11]. ORF3 encodes minor capsid proteins (VP2), which are involved in capsid assembly and genome encapsidation [7,8,12]. The genetic classification of noroviruses is based on VP1 and RdRp [7,8]. There are 10 genogroups (GI–GX) and 49 norovirus genotypes, among which GII genotype 4 (GII.4) is responsible for most norovirus outbreaks worldwide [8].
Previously, research into human norovirus (HuNoV) pathogenesis has been hampered because it could not be propagated successfully in cell culture [5]. Murine norovirus (MNV) and feline calicivirus (FCV) have been utilized as surrogates to circumvent this barrier [6,13] owing to their shared genetic and biochemical features with HuNoV [6,14]. According to recent research, HuNoV and FCV have post-translational modifications (PTMs) in their RdRp, VPg, and P domains [11,15,16]. Moreover, human intestinal enteroids (HIEs) generated from stem cells and zebrafish larvae are effective HuNoV replication models [17,18,19,20]. These systems have the potential to give a better understanding of HuNoV biology, pathophysiology, and underlying mechanisms of infection and PTMs. Infections in HIE cultures indicate the link between HBGA glycosylation and norovirus infection [21]. On positive-sense RNA viruses, modification of the cellular translational apparatus occurs, which is thought to be favorable for viral infection [16,22]. However, knowledge of norovirus modifications has not yet been systematically organized.
Thus, we outline the current understanding of PTMs and explore their influence on norovirus pathogenesis. We comprehensively discuss in particular the mechanisms by which phosphorylation, N- and O-glycosylation, and O-GlcNAcylation affect norovirus pathogenesis and raise the issue of a lack of information on modifications of noroviruses.

2. Post-Translational Modifications

2.1. Effects of Post-Translational Modifications on Protein Function

Protein PTMs provide crucial insights into various cellular functions [23]. PTMs are typically formed by enzymatic processes that add functional groups to the side chains of amino acids [24]. These modifications are reversible and essential for biological functions. Over 620 modifications have been discovered that occur after protein synthesis [25]. N- and O-glycosylation, O-GlcNAcylation, and phosphorylation are the most common modifications that increase protein solubility, conformation, interactions, signaling, and degradation, which are all critical for cell growth [26]. N- and O-glycosylation facilitates receptor binding and alters the structure of the secreted proteins [27,28]. In contrast, O-GlcNAcylation and phosphorylation are competitive processes implicated in many signal transduction pathways [29,30].

2.2. Effects of Post-Translational Modifications on Viruses

Many pathogens, including viruses and bacteria, can utilize post-translational modifications to enhance interactions with host proteins crucial to infection (Table 1). As viruses rely on the protein synthesis machinery of host cells to support their replication, most viral proteins are subjected to PTMs [31]. This improves viral replication, assembly, release, and immune escape during infection, thereby promoting virus propagation. Furthermore, PTMs improve solubility and antigenicity, which enhances virulence [29]. For example, phosphorylation of the dengue virus (DENV) type 2 regulates interactions between viral replication proteins [22]. In this review, we elucidate the effects of PTMs on noroviruses. Here, we focus on the mechanism of N- and O-glycosylation, O-GlcNAcylation, and phosphorylation and discuss the mechanisms by which these modifications affect norovirus pathogenesis.

2.3. Identification of Post-Translational Modifications

Previously, studies on PTMs were limited owing to the requirement for laborious biochemical approaches, including radioactive-isotope-labeled substrates, antibody-based Western blot analysis, and peptide and protein arrays [57,58,59]. However, these procedures are inefficient owing to the difficulty in identifying modified proteins using their corresponding weakly radioactive-isotope-labeled substrates. Furthermore, creating antibodies that recognize the minor structural motifs of particular PTMs using antibody-based Western blot analysis is also challenging [59]. Over the last decade, mass spectrometry (MS) has been demonstrated to be a powerful technique for identifying modified proteins and mapping PTM locations. Sites containing N- and O-glycosylation, O-GlcNAcylation, and phosphorylation modifications were enriched and successfully identified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) [59,60,61]. In addition, enzymes or inhibitors may be used to investigate PTMs (Table 1). Section 3.1, Section 4.1 and Section 5.1 in this article comprehensively describe these mechanisms.

3. N- and O-Glycosylation

3.1. N- and O-Glycosylation on Proteins

Glycosylation is a multienzymatic process that produces various glycoconjugates covalently bound to lipids or proteins [62]. Glycosylation is classified as N-linked or O-linked [30] (Figure 1). The first step in N-linked glycosylation is the attachment of an N-linked glycan to the asparagine residue of a nascent polypeptide chain by oligosaccharyltransferase (OST) in the endoplasmic reticulum (ER). Other enzymes subsequently construct glycans, resulting in a diverse spectrum of glycan structures such as oligomannose, hybrid, and complex-type N-glycan structures [30,45,62]. In O-linked glycosylation, N-acetylgalactosamine (GalNAc) is covalently linked to the hydroxyl group of serine or threonine residues in the Golgi apparatus [45,63]. This process is mediated by 20 different GalNAc transferases, each of which may produce unique mucin-type O-glycan core structures [45]. N- and O-glycosylation can alter protein characteristics, such as stability, solubility, protease resistance, and biological activity [64]. For example, glycans can be structurally integrated into the protein fold and exhibit significant glycan–protein interactions to stabilize the protein [30].
Traditional N-glycosylation detection methods include mutagenesis of anticipated glycosylation sites and enzymes to cleave glycans from protein substrates, which aids in distinguishing between terminally and core-glycosylated N-glycans. The peptide-N-glycosidase F (PNGase F) specifically cleaves the linkage between the innermost GlcNAc and asparagine. In addition, endoglycosidase H cleaves within the chitobiose core of high mannose and some hybrid oligosaccharides from N-linked glycoproteins. The molecular weight and functionalities of an N-glyco protein can be altered after incubation with these N-glycan removal enzymes (Table 1). Tunicamycin, for example, acts as an analog of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) to inhibit dolichol phosphate-dependent N-acetylglucosamine 1-phospho-transferase (DPAGT1), thus preventing the first step in N-glycoprotein biosynthesis [65]. In addition to the approaches stated above, gel electrophoresis and immunoblotting with antibodies are practical since PTM with glycan moieties changes the electrophoretic mobility of the protein [63].
Enrichment and MS technologies are used in modern strategies for detecting glycoproteins. Most N-glycoprotein enrichment procedures are based on hydrazide chemistry, which involves oxidation of the carbohydrate side chain and conjugating glycopeptides to hydrazide resin [66]. The isolated glycopeptides are then released using a glycan-specific enzyme, such as peptide-N-glycosidase F (PNGase F), followed by MS identification, thereby facilitating a comprehensive analysis of the N-glycosylated proteome [59,63,67]. Using the GlycoStore database, approximately 850 unique glycan structures of glycoproteins and glycolipids can be determined [68]. Alternatively, the use of data-independent collection mode mass spectrometry (MSE) and ProteinLynx Global Server (PLGS) software (Waters Corporation, Milford, MA, USA) may help identify short glycopeptides [28,69]. As for the identification of complicated N-glycans, PNGase F can liberate glycans and subsequently label them with the fluorophore 2-aminobenzoic acid (2-AA). The 2-AA tagged glycans can be purified by solid-phase extraction and detected using a fluorescence detector or mass spectrometer [70].

3.2. N- and O-Glycosylation on Viruses

Flaviviruses, severe acute respiratory syndrome-associated coronavirus (SARS-CoV2), influenza viruses, and rotaviruses exhibit viral protein N- and O-glycosylation (Table 1), which aids in viral entry, assembly, transmission potential, virulence, and pathogenicity [30]. RNA viruses manufacture their envelopes and surface glycoproteins using the host ER/Golgi system. Additionally, N-linked glycans can facilitate the folding and trafficking of viral glycoproteins via host ER quality control [71]. Viruses are often highly glycosylated on their surfaces, which increases the attachment of viral proteins to cells and facilitates infection [64]. Furthermore, they can mask or modify antibody-mediated recognition of antigenic epitopes, helping them evade the immune system of the host [64,71].
For example, glycosylation of the DENV NS1 aids in protein secretion by forming hexamers that bind to lectin pathway proteins such as C1s, C4, C4b-binding protein (C4BP), and mannose-binding lectin (MBL). This modification assists immune evasion by limiting lectin complement activation and DENV neutralization, controlling pathogenesis, and contributing to virulence [30,36,72]. In SARS-CoV-2, the spike protein, as well as M and E proteins, are glycosylated and responsible for membrane fusion, invasion, and immune escape [35,43]. The spike protein is attached by N-glycan, which facilitates its entry into the host cells and protects the epitopes to evade the immune response [43,44]. N-linked and O-linked glycosylation of the M protein facilitates viral particle assembly and budding. The E protein is involved in many viral processes, including membrane construction and interactions with other membrane proteins, and has two glycosylation sites, N48 and N66 [35].

3.3. Glycosylation on Noroviruses

HBGA is essential for norovirus infection. Fucosyltransferase 2 (FUT2), an enzyme that catalyzes 1,2-fucosylation of terminal galactose, regulates the production of HBGAs in intestinal epithelial cells. Individuals who lack FUT2s do not express HBGAs on their epithelial cells, rendering them exceptionally resistant to the gastroenteritis caused by certain norovirus strains, such as GII genotype 4 (Figure 1). Several pandemic GII.4 variations have been identified, including GII.4 US95/96, GII.4 Farmington Hills2002, GII.4 Hunter2004, GII.4 Yerseke2006a, GII.4 Den Haag2006b, GII.4 New Orleans2009, and GII.4 Sydney2012 [21,73]. Recently, non-GII.4 genotypes, including the GII.17 variant and the GII.2[P16] recombinant strain, have also been reported to cause epidemics [74,75]. The GII.17 variant caused norovirus outbreaks in some Asian countries, replacing the GII.4 Sydney2012 [74]. Moreover, the GII.2[P16] recombinant strain is reported to have swept through Japan, China, and Germany [75,76,77]. Despite the fact that HBGA glycosylation significantly alters binding affinity, little is revealed about the N- and O-glycosylation of norovirus capsid protein VP1, which merits additional exploration. On the other hand, the deamidation of Asn373 and the formation of isoD373 on the norovirus capsid protein VP1 impair its recognition of HBGAs [11] (Figure 1). Asn373 is found in the antigenic loop next to the HBGA binding site. Asn373 interacts with the glycan ligand through two direct hydrogen bonds; when converted to isoD373, only one hydrogen bond remains [78]. In addition, the peptides that contain isoD373 in the P dimmer domain do not show elevated flexibility [79]. Thus, the formation of isoD373 decreases the binding affinity of the P protein for HBGAs.
Viruses 15 00798 g001 550
Figure 1. Replication cycle of noroviruses and protein post-translational modifications. (1) Attachment: Human norovirus (HuNoV) attaches to the HBGAs on the host cell surface, allowing viral entrance. Note that fucosylation of HBGA by fucosyltransferase 2 (FUT2) is required for certain genotypes of norovirus infection. In contrast, deamination on Asn373 of norovirus capsid protein VP1 impairs the recognition of HBGAs. (2) Binding. (3) Uncoating through undefined pathways [80]. (4) Translation: The positive-sense RNA genome may serve as a template for viral protein translation. After translation, viral proteins could undergo N- or O-glycosylation at the endoplasmic reticulum or Golgi apparatus. Mechanisms of noroviral protein glycosylation remain unclear. (5) Assembly: viral proteins assemble to form new viral particles. (6) Release: viral particle release from host cell [81]. Abbreviations: HBGA, histo-blood group antigen.
Figure 1. Replication cycle of noroviruses and protein post-translational modifications. (1) Attachment: Human norovirus (HuNoV) attaches to the HBGAs on the host cell surface, allowing viral entrance. Note that fucosylation of HBGA by fucosyltransferase 2 (FUT2) is required for certain genotypes of norovirus infection. In contrast, deamination on Asn373 of norovirus capsid protein VP1 impairs the recognition of HBGAs. (2) Binding. (3) Uncoating through undefined pathways [80]. (4) Translation: The positive-sense RNA genome may serve as a template for viral protein translation. After translation, viral proteins could undergo N- or O-glycosylation at the endoplasmic reticulum or Golgi apparatus. Mechanisms of noroviral protein glycosylation remain unclear. (5) Assembly: viral proteins assemble to form new viral particles. (6) Release: viral particle release from host cell [81]. Abbreviations: HBGA, histo-blood group antigen.
Viruses 15 00798 g001

4. O-GlcNAcylation

4.1. O-GlcNAcylation on Proteins

O-GlcNAcylation is a type of noncanonical glycosylation whereby O-linked N-acetylglucosamine (O-GlcNAc) is coupled to the hydroxyl groups of serine or threonine residues in proteins [82,83]. The hexosamine biosynthetic pathway, which incorporates glucose, amino acids, fatty acids, and nucleotide metabolism, produces the donor sugar for O-GlcNAcylation, UDP-GlcNAc. O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) catalyze the addition and removal of O-GlcNAc, respectively [84] (Figure 2). These two enzymes are found in all multicellular organisms and are substantially conserved from worms to humans [85]. In contrast to glycosylation, which is stable and localizes mainly at the ER and Golgi apparatus, O-GlcNAcylation is reversible and occurs in the cytoplasm [82]. O-GlcNAcylation has been implicated in several biological activities, including transcription, translation, metabolism, signal transmission, and apoptosis [84].
O-GlcNAcylation can be detected using various techniques such as lectins, antibodies, or click chemistry-based approaches. Lectins, such as Concanavalin A wheat germ agglutinin (WGA), are primarily used for binding to sialic acids and terminal β-GlcNAc on complex glycans [86,87,88]. Metabolic or chemical labeling followed by conjugation to an affinity linker, such as biotin or streptavidin, is a valuable method for detecting O-GlcNAcylation when combined with MS. In addition, some specific enzymes, such as galactosyltransferase, can selectively label the modified sites with a ketone-containing galactose analog, which also helps to identify this modification [87].

4.2. O-GlcNAcylation on Viruses

Unlike N- and O-glycosylation, which appears on the surface of viruses, O-GlcNAcylation occurs on proteins surrounding the nucleic acid components of viruses [85]. For example, multiple sites on the basic phosphoprotein of human cytomegalovirus are O-GlcNAcylated (Table 1) [50]. Furthermore, O-GlcNAcylation occurs in rotaviruses, where O-GlcNAc has been detected in RNA polymerase II transcription factors [47]. This modification is also present in adenoviruses and insect viruses, such as baculoviruses [48]. The implications of O-GlcNAcylation include playing a regulatory function, stabilizing multiprotein complexes, and conferring proteolytic resistance [82]. There have been few investigations of viral protein O-GlcNAcylation; nevertheless, the roles of O-GlcNAcylation in viruses are worth investigating further.

4.3. O-GlcNAcylation on Noroviruses

Most enveloped viruses have glycosylated surface proteins; however, only a few nonenveloped viruses have glycoproteins in their capsids. Noroviruses fall within the latter category. In 2022, several potential modification sites were discovered to be adjacent to the amino acid of the S domain (Thr65, Ser67) and P domain (Thr238, Ser519 in the P1 domain, and Thr350, Thr369, Thr371, Thr381 in the P2 domain), which may be relevant for receptor interactions [46] (Figure 2). The modifications were obtained by MALDI-MS of ethylaminylated peptides from the noroviral VP1 or by LC–MS2 sequencing on the native glycopeptides. Using immunoassays with lectins and antibodies, the authors confirmed the O-GlcNAcylation on VP1 protein. Based on this research, we speculate that O-GlcNAcylation may affect the binding affinity of noroviruses on the HBGAs. Several studies have revealed an interaction between O-GlcNAcylation and phosphorylation [85,89]. However, we lack sufficient studies on O-GlcNAcylation, although there are sufficient reports on norovirus phosphorylation.

5. Phosphorylation

5.1. Phosphorylation vs. O-GlcNAcylation

Protein phosphorylation is a well-known primary reversible switch for cell signaling control that plays an essential role in various cellular processes. Unlike O-GlcNAcylation, which OGT and OGA control, phosphorylation uses a myriad of protein kinases to transfer γ-phosphate from adenosine triphosphate (ATP) to the amino acid residue in the substrate protein (Figure 3). The phosphorylation of substrate proteins may occur at one or more sites. Nine amino acids are used as phosphate acceptors, including serine, threonine, and tyrosine (which contain hydroxyl groups (-OH), basic histidine, arginine, lysine, and acidic aspartic acid, glutamic acid, and cysteine. O-phosphorylation of serine, threonine, or tyrosine residues forms a phosphodiester (P-O) link between the -OH and the γ-phosphate of ATP. N-phosphorylation of the histidine, arginine, or lysine residues forms a phosphoramidite (P-N) link between the -NH and the γ-phosphate of ATP. O-phosphorylation is stable. In contrast, N-phosphorylation is acid-labile and, consequently, difficult to detect [90]. Adding a phosphate group to an amino acid residue substantially alters the protein structure. Phosphorylation affects protein characteristics such as enzymatic activity, stability, subcellular localization, and interaction with binding partners [22,91].
One of the most common approaches for detecting phosphorylation is to use radioactive-isotope-labeled substrates such as P 32 orthophosphate. Furthermore, Western blot analysis and arrays have been used to detect phosphorylation. However, these techniques cannot provide information about the phosphorylation sites [59]. Mass spectrometry, coupled with enrichment techniques, has proven to be more robust in identifying PTM substrates and mapping PTM locations [59,63]. Because the overall proteome contains only a small fraction of phosphorylated proteins/peptides, enrichment is an essential step in MS detection of phosphorylation. Antibody-based affinity enrichment and ionic-interaction-based enrichment are the two enrichment procedures [59,92]. The use of pan-PTM antibodies to identify PTM peptides has been proven effective for tyrosine phosphorylation [88]. Furthermore, the interaction between the phosphate group and immobilized metal ions or titanium dioxide (TiO2) is the most common enrichment technique for analyzing phosphorylated peptides by MS, which recognizes over 3000 unique phosphopeptides [59,93,94,95].
As the density of co-occurring PTMs on proteins is high, several PTMs can affect the action of another via a process termed PTM crosstalk [83]. The most documented form is the PTM crosstalk between phosphorylation and O-GlcNAcylation (Figure 3). As they occur primarily on the same amino acid residues (serine and threonine), these two PTMs undergo crosstalk. Crosstalk may happen in various ways, including competition for the same site/residue (reciprocal crosstalk) and modifications affecting each other (proximal or distal to the peptide sequences) [83]. Furthermore, interruption of phosphorylation events alters the GlcNAcylation levels and vice versa. These findings demonstrate crosstalk between the two modifications [83,89].

5.2. Phosphorylation on Viruses

Many intracellular obligatory pathogens require phosphorylation to initiate a productive infection cycle [22]. The phosphorylation of viral proteins affects viral–host interactions, which substantially impact viral infection, replication, and cytotoxicity [30]. The PTMs of viral proteins, particularly RdRps, are common. Hepatitis C virus (HCV) RdRp, for example, is phosphorylated by protein kinase C-related kinase 2 (PRK2), which is essential for effective viral replication [91,96]. The viral RdRp enzyme is the main enzyme involved in viral RNA genome replication in plus-strand RNA viruses, including noroviruses [97]. RdRp phosphorylation has been proposed to be functionally connected to viral replication [16,98].

5.3. Phosphorylation on Noroviruses

Phosphorylation is widely recognized for directly regulating viral protein activity and acting as a molecular signal for a binding partner. Norovirus RdRp and FCV VPg proteins are reportedly phosphorylated. RdRp is phosphorylated at a position (Thr33) at the interface of the RdRp finger and thumb domains. This modification is exclusive to the most common norovirus genotypes, including GII.4 and GII.b [16]. The phosphorylation sites of the FCV VPg protein are threonine at position 80 and serine at position 107. These polymerases and virus-encoded proteins are required for viral function. RdRp, found in viral particles, is responsible for viral genome transcription and replication. VPg interacts with NS7 to help viral RNA synthesis, whereas its interaction with eIF4A triggers viral protein synthesis and VP1 functioning in viral encapsidation [15,99]. Both RdRp and VPg play essential roles in viral evolution and fitness. Consequently, the phosphorylation of RdRp and VPg may provide a mechanism for noroviruses and FCV, respectively, to regulate the viral life cycle and impact viral pathogenicity.

6. Conclusions

PTMs enable viruses to regulate molecular functions by maintaining stability, interacting with receptors, and suppressing the immune system. Many RNA viruses feature PTMs, as shown by previous studies; however, the understanding of norovirus PTMs remains poorly elucidated. Research suggests that phosphorylation promotes norovirus pathogenicity; however, information on glycosylation and O-GlcNAcylation is limited. Investigating the factors behind this conclusion is worthwhile because phosphorylation and O-GlcNAcylation frequently interact. One reason for this might be that only a few nonenveloped viruses exhibit glycosylation and O-GlcNAcylation. Furthermore, the potential for O-GlcNAcylation varies from cell to cell. The host cell type should be considered when analyzing viral glycosylation, and sophisticated mass spectrometry tools can aid the investigation. Given that glycosylation, O-GlcNAcylation, and phosphorylation are all associated with viral pathogenicity, identifying the modification sites on noroviruses will aid in developing future vaccines and treatments.

Author Contributions

Conceptualization, C.-C.C. and L.-Y.K.; validation, G.-M.K. and P.-Y.C.; investigation, G.-M.K.; resources, P.-Y.C. and L.-Y.K.; writing—original draft preparation, C.-C.C.; writing—review and editing, G.-M.K. and L.-Y.K.; visualization, C.-C.C. and L.-Y.K.; supervision, P.-Y.C. and L.-Y.K.; project administration, G.-M.K. and P.-Y.C.; funding acquisition, G.-M.K. and L.-Y.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by grants from the Kaohsiung Medical University (KMU-DK(A)111002 to L.-Y.K.) and the Taiwan Ministry of Science and Technology (NSTC-111-2320-B-037-023- to L.-Y.K.).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data that support the findings of this study are available in the material of this article.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

DENVDengue virus
DPAGT1Dolichol phosphate-dependent N-acetylglucosamine 1-phospho-transferase
EREndoplasmic reticulum
Endo HEndoglycosidase H
Endo HFEndo-β-N-acetylglucosaminidase H
FCVFeline calicivirus
FUT2Fucosyltransferase 2
GalNAcN-acetylgalactosamine
GC-MSGas chromatography-mass spectrometry
HBGAHisto-blood group antigen
HCVHepatitis C virus
HILICHydrophilic interaction liquid chromatography
HIV-1Human immunodeficiency virus-1
HuNoVHuman norovirus
LC-MSLiquid chromatography-mass spectrometry
MBLMannose-binding lectin
MNVMurine norovirus
MSMass spectrometry
MSEData-independent collection mode mass spectrometry
NSNonstructural protein
O-GlcNAcO-linked N-acetylglucosamine
OGAO-GlcNAcase
OGTO-GlcNAc transferase
ORFOpen reading frame
OSTOligosaccharyltransferase
PLGSProtein Lynx Global Server
PNGase FPeptide-N-glycosidase F
PTMPost-translational modification
RdRpRNA-dependent RNA polymerase
RNARibonucleic acid
SARS-CoVSevere acute respiratory syndrome-associated coronavirus
UDP-GlcNAcUridine diphosphate N-acetylglucosamine
UPLCUltraperformance liquid chromatography
WGAWheat germ agglutinin
ZIKVZika virus

References

  1. Lucero, Y.; Matson, D.O.; Ashkenazi, S.; George, S.; O’Ryan, M. Norovirus: Facts and Reflections from Past, Present, and Future. Viruses 2021, 13, 2399. [Google Scholar] [CrossRef] [PubMed]
  2. Lopman, B.A.; Steele, D.; Kirkwood, C.D.; Parashar, U.D. The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control. PLoS Med. 2016, 13, e1001999. [Google Scholar] [CrossRef] [PubMed]
  3. Pires, S.M.; Fischer-Walker, C.L.; Lanata, C.F.; Devleesschauwer, B.; Hall, A.J.; Kirk, M.D.; Duarte, A.S.; Black, R.E.; Angulo, F.J. Aetiology-Specific Estimates of the Global and Regional Incidence and Mortality of Diarrhoeal Diseases Commonly Transmitted through Food. PLoS ONE 2015, 10, e0142927. [Google Scholar] [CrossRef] [PubMed]
  4. Estes, M.K.; Prasad, B.V.; Atmar, R.L. Noroviruses everywhere: Has something changed? Curr. Opin. Infect. Dis. 2006, 19, 467–474. [Google Scholar] [CrossRef] [PubMed]
  5. Glass, R.I.; Parashar, U.D.; Estes, M.K. Norovirus gastroenteritis. N. Engl. J. Med. 2009, 361, 1776–1785. [Google Scholar] [CrossRef] [Green Version]
  6. Netzler, N.E.; Enosi Tuipulotu, D.; White, P.A. Norovirus antivirals: Where are we now? Med. Res. Rev. 2019, 39, 860–886. [Google Scholar] [CrossRef] [PubMed]
  7. Thorne, L.G.; Goodfellow, I.G. Norovirus gene expression and replication. J. Gen. Virol. 2014, 95 Pt 2, 278–291. [Google Scholar] [CrossRef]
  8. Chhabra, P.; de Graaf, M.; Parra, G.I.; Chan, M.C.; Green, K.; Martella, V.; Wang, Q.; White, P.A.; Katayama, K.; Vennema, H.; et al. Updated classification of norovirus genogroups and genotypes. J. Gen. Virol. 2019, 100, 1393–1406. [Google Scholar] [CrossRef]
  9. Cao, S.; Lou, Z.; Tan, M.; Chen, Y.; Liu, Y.; Zhang, Z.; Zhang, X.C.; Jiang, X.; Li, X.; Rao, Z. Structural basis for the recognition of blood group trisaccharides by norovirus. J. Virol. 2007, 81, 5949–5957. [Google Scholar] [CrossRef] [Green Version]
  10. Hutson, A.M.; Atmar, R.L.; Marcus, D.M.; Estes, M.K. Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J. Virol. 2003, 77, 405–415. [Google Scholar] [CrossRef] [Green Version]
  11. Mallagaray, A.; Creutznacher, R.; Dülfer, J.; Mayer, P.H.O.; Grimm, L.L.; Orduña, J.M.; Trabjerg, E.; Stehle, T.; Rand, K.D.; Blaum, B.S.; et al. A post-translational modification of human Norovirus capsid protein attenuates glycan binding. Nat. Commun. 2019, 10, 1320. [Google Scholar] [CrossRef] [Green Version]
  12. Bányai, K.; Estes, M.K.; Martella, V.; Parashar, U.D. Viral gastroenteritis. Lancet 2018, 392, 175–186. [Google Scholar] [CrossRef] [PubMed]
  13. Vashist, S.; Bailey, D.; Putics, A.; Goodfellow, I. Model systems for the study of human norovirus Biology. Future Virol. 2009, 4, 353–367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Wobus, C.E.; Karst, S.M.; Thackray, L.B.; Chang, K.O.; Sosnovtsev, S.V.; Belliot, G.; Krug, A.; Mackenzie, J.M.; Green, K.Y.; Virgin, H.W. Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2004, 2, e432. [Google Scholar] [CrossRef] [PubMed]
  15. Olspert, A.; Hosmillo, M.; Chaudhry, Y.; Peil, L.; Truve, E.; Goodfellow, I. Protein-RNA linkage and posttranslational modifications of feline calicivirus and murine norovirus VPg proteins. PeerJ 2016, 4, e2134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Eden, J.S.; Sharpe, L.J.; White, P.A.; Brown, A.J. Norovirus RNA-dependent RNA polymerase is phosphorylated by an important survival kinase, Akt. J. Virol. 2011, 85, 10894–10898. [Google Scholar] [CrossRef] [Green Version]
  17. Ettayebi, K.; Tenge, V.R.; Cortes-Penfield, N.W.; Crawford, S.E.; Neill, F.H.; Zeng, X.L.; Yu, X.; Ayyar, B.V.; Burrin, D.; Ramani, S.; et al. New Insights and Enhanced Human Norovirus Cultivation in Human Intestinal Enteroids. mSphere 2021, 6, e01136-20. [Google Scholar] [CrossRef]
  18. Lin, S.C.; Qu, L.; Ettayebi, K.; Crawford, S.E.; Blutt, S.E.; Robertson, M.J.; Zeng, X.L.; Tenge, V.R.; Ayyar, B.V.; Karandikar, U.C.; et al. Human norovirus exhibits strain-specific sensitivity to host interferon pathways in human intestinal enteroids. Proc. Natl. Acad. Sci. USA 2020, 117, 23782–23793. [Google Scholar] [CrossRef]
  19. Van Dycke, J.; Ny, A.; Conceicao-Neto, N.; Maes, J.; Hosmillo, M.; Cuvry, A.; Goodfellow, I.; Nogueira, T.C.; Verbeken, E.; Matthijnssens, J.; et al. A robust human norovirus replication model in zebrafish larvae. PLoS Pathog. 2019, 15, e1008009. [Google Scholar] [CrossRef] [Green Version]
  20. Mirabelli, C.; Santos-Ferreira, N.; Gillilland, M.G., 3rd; Cieza, R.J.; Colacino, J.A.; Sexton, J.Z.; Neyts, J.; Taube, S.; Rocha-Pereira, J.; Wobus, C.E. Human Norovirus Efficiently Replicates in Differentiated 3D-Human Intestinal Enteroids. J. Virol. 2022, 96, e0085522. [Google Scholar] [CrossRef]
  21. Haga, K.; Ettayebi, K.; Tenge, V.R.; Karandikar, U.C.; Lewis, M.A.; Lin, S.C.; Neill, F.H.; Ayyar, B.V.; Zeng, X.L.; Larson, G.; et al. Genetic Manipulation of Human Intestinal Enteroids Demonstrates the Necessity of a Functional Fucosyltransferase 2 Gene for Secretor-Dependent Human Norovirus Infection. mBio 2020, 11, e00251-20. [Google Scholar] [CrossRef] [Green Version]
  22. Jakubiec, A.; Jupin, I. Regulation of positive-strand RNA virus replication: The emerging role of phosphorylation. Virus Res. 2007, 129, 73–79. [Google Scholar] [CrossRef]
  23. Mann, M.; Jensen, O.N. Proteomic analysis of post-translational modifications. Nat. Biotechnol. 2003, 21, 255–261. [Google Scholar] [CrossRef] [PubMed]
  24. Walsh, C.T.; Garneau-Tsodikova, S.; Gatto, G.J., Jr. Protein posttranslational modifications: The chemistry of proteome diversifications. Angew. Chem. Int. Ed. Engl. 2005, 44, 7342–7372. [Google Scholar] [CrossRef] [PubMed]
  25. Xu, H.; Wang, Y.; Lin, S.; Deng, W.; Peng, D.; Cui, Q.; Xue, Y. PTMD: A Database of Human Disease-associated Post-translational Modifications. Genom. Proteom. Bioinform. 2018, 16, 244–251. [Google Scholar] [CrossRef] [PubMed]
  26. Ryšlavá, H.; Doubnerová, V.; Kavan, D.; Vaněk, O. Effect of posttranslational modifications on enzyme function and assembly. J. Proteom. 2013, 92, 80–109. [Google Scholar] [CrossRef] [PubMed]
  27. Gao, Y.; Luan, X.; Melamed, J.; Brockhausen, I. Role of Glycans on Key Cell Surface Receptors That Regulate Cell Proliferation and Cell Death. Cells 2021, 10, 1252. [Google Scholar] [CrossRef] [PubMed]
  28. Ke, L.Y.; Chan, H.C.; Chen, C.C.; Chang, C.F.; Lu, P.L.; Chu, C.S.; Lai, W.T.; Shin, S.J.; Liu, F.T.; Chen, C.H. Increased APOE glycosylation plays a key role in the atherogenicity of L5 low-density lipoprotein. FASEB J. 2020, 34, 9802–9813. [Google Scholar] [CrossRef]
  29. Leutert, M.; Entwisle, S.W.; Villen, J. Decoding Post-Translational Modification Crosstalk With Proteomics. Mol. Cell. Proteom. 2021, 20, 100129. [Google Scholar] [CrossRef]
  30. Kumar, R.; Mehta, D.; Mishra, N.; Nayak, D.; Sunil, S. Role of Host-Mediated Post-Translational Modifications (PTMs) in RNA Virus Pathogenesis. Int. J. Mol. Sci. 2020, 22, 323. [Google Scholar] [CrossRef]
  31. Ikram, A.; Rauff, B.; Alzahrani, B.; Awan, F.M.; Obaid, A.; Naz, A.; Kakar, S.J.; Janjua, H.A. Integrated analysis to study the interplay between post-translational modifications (PTM) in hepatitis C virus proteins and hepatocellular carcinoma (HCC) development. Sci. Rep. 2022, 12, 15648. [Google Scholar] [CrossRef] [PubMed]
  32. Reynard, O.; Borowiak, M.; Volchkova, V.A.; Delpeut, S.; Mateo, M.; Volchkov, V.E. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J. Virol. 2009, 83, 9596–9601. [Google Scholar] [CrossRef] [Green Version]
  33. Binley, J.M.; Ban, Y.E.; Crooks, E.T.; Eggink, D.; Osawa, K.; Schief, W.R.; Sanders, R.W. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J. Virol. 2010, 84, 5637–5655. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Ritchie, G.; Harvey, D.J.; Feldmann, F.; Stroeher, U.; Feldmann, H.; Royle, L.; Dwek, R.A.; Rudd, P.M. Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein. Virology 2010, 399, 257–269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Aloor, A.; Aradhya, R.; Venugopal, P.; Gopalakrishnan Nair, B.; Suravajhala, R. Glycosylation in SARS-CoV-2 variants: A path to infection and recovery. Biochem. Pharmacol. 2022, 206, 115335. [Google Scholar] [CrossRef] [PubMed]
  36. Flamand, M.; Megret, F.; Mathieu, M.; Lepault, J.; Rey, F.A.; Deubel, V. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J. Virol. 1999, 73, 6104–6110. [Google Scholar] [CrossRef] [Green Version]
  37. Zhao, D.; Liang, L.; Wang, S.; Nakao, T.; Li, Y.; Liu, L.; Guan, Y.; Fukuyama, S.; Bu, Z.; Kawaoka, Y.; et al. Glycosylation of the Hemagglutinin Protein of H5N1 Influenza Virus Increases Its Virulence in Mice by Exacerbating the Host Immune Response. J. Virol. 2017, 91, e02215-16. [Google Scholar] [CrossRef] [Green Version]
  38. Nurdin, J.A.; Kotaki, T.; Kawagishi, T.; Sato, S.; Yamasaki, M.; Nouda, R.; Minami, S.; Kanai, Y.; Kobayashi, T. N-Glycosylation of Rotavirus NSP4 Protein Affects Viral Replication and Pathogenesis. J. Virol. 2023, 97, e01861-22. [Google Scholar] [CrossRef]
  39. Carbaugh, D.L.; Baric, R.S.; Lazear, H.M. Envelope Protein Glycosylation Mediates Zika Virus Pathogenesis. J. Virol. 2019, 93, e00113-19. [Google Scholar] [CrossRef] [Green Version]
  40. Watanabe, Y.; Berndsen, Z.T.; Raghwani, J.; Seabright, G.E.; Allen, J.D.; Pybus, O.G.; McLellan, J.S.; Wilson, I.A.; Bowden, T.A.; Ward, A.B.; et al. Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nat. Commun. 2020, 11, 2688. [Google Scholar] [CrossRef]
  41. Stewart-Jones, G.B.; Soto, C.; Lemmin, T.; Chuang, G.Y.; Druz, A.; Kong, R.; Thomas, P.V.; Wagh, K.; Zhou, T.; Behrens, A.J.; et al. Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell 2016, 165, 813–826. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Sommerstein, R.; Flatz, L.; Remy, M.M.; Malinge, P.; Magistrelli, G.; Fischer, N.; Sahin, M.; Bergthaler, A.; Igonet, S.; Ter Meulen, J.; et al. Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathog. 2015, 11, e1005276. [Google Scholar] [CrossRef] [PubMed]
  43. Casas-Sanchez, A.; Romero-Ramirez, A.; Hargreaves, E.; Ellis, C.C.; Grajeda, B.I.; Estevao, I.L.; Patterson, E.I.; Hughes, G.L.; Almeida, I.C.; Zech, T.; et al. Inhibition of Protein N-Glycosylation Blocks SARS-CoV-2 Infection. mBio 2022, 13, e0371821. [Google Scholar] [CrossRef] [PubMed]
  44. Grant, O.C.; Montgomery, D.; Ito, K.; Woods, R.J. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci. Rep. 2020, 10, 14991. [Google Scholar] [CrossRef] [PubMed]
  45. Watanabe, Y.; Bowden, T.A.; Wilson, I.A.; Crispin, M. Exploitation of glycosylation in enveloped virus pathobiology. Biochim. Biophys. Acta Gen. Subj. 2019, 1863, 1480–1497. [Google Scholar] [CrossRef]
  46. Hanisch, F.G. Recombinant norovirus capsid protein VP1 (GII.4) expressed in H5 insect cells exhibits post-translational modifications with potential impact on lectin activity and vaccine design. Glycobiology 2022, 32, 496–505. [Google Scholar] [CrossRef]
  47. González, S.A.; Burrone, O.R. Rotavirus NS26 is modified by addition of single O-linked residues of N-acetylglucosamine. Virology 1991, 182, 8–16. [Google Scholar] [CrossRef]
  48. Whitford, M.; Faulkner, P. A structural polypeptide of the baculovirus Autographa californica nuclear polyhedrosis virus contains O-linked N-acetylglucosamine. J. Virol. 1992, 66, 3324–3329. [Google Scholar] [CrossRef] [Green Version]
  49. Caillet-Boudin, M.L.; Strecker, G.; Michalski, J.C. O-linked GlcNAc in serotype-2 adenovirus fibre. Eur. J. Biochem. 1989, 184, 205–211. [Google Scholar] [CrossRef]
  50. Greis, K.D.; Gibson, W.; Hart, G.W. Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952. J. Virol. 1994, 68, 8339–8349. [Google Scholar] [CrossRef] [Green Version]
  51. Takamatsu, Y.; Yoshikawa, T.; Kurosu, T.; Fukushi, S.; Nagata, N.; Shimojima, M.; Ebihara, H.; Saijo, M.; Noda, T. Role of VP30 Phosphorylation in Ebola Virus Nucleocapsid Assembly and Transport. J. Virol. 2022, 96, e0108322. [Google Scholar] [CrossRef] [PubMed]
  52. Hsu, S.C.; Tsai, C.N.; Lee, K.Y.; Pan, T.C.; Lo, C.W.; Yu, M.J. Sequential S232/S235/S238 Phosphorylation of the Hepatitis C Virus Nonstructural Protein 5A. J. Virol. 2018, 92, e01295-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Yeh, J.X.; Park, E.; Schultz, K.L.W.; Griffin, D.E. NF-κB Activation Promotes Alphavirus Replication in Mature Neurons. J. Virol. 2019, 93, e01071-19. [Google Scholar] [CrossRef]
  54. Surjit, M.; Kumar, R.; Mishra, R.N.; Reddy, M.K.; Chow, V.T.; Lal, S.K. The severe acute respiratory syndrome coronavirus nucleocapsid protein is phosphorylated and localizes in the cytoplasm by 14-3-3-mediated translocation. J. Virol. 2005, 79, 11476–11486. [Google Scholar] [CrossRef] [Green Version]
  55. Mazzon, M.; Jones, M.; Davidson, A.; Chain, B.; Jacobs, M. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J. Infect. Dis. 2009, 200, 1261–1270. [Google Scholar] [CrossRef] [Green Version]
  56. Ziegler, C.M.; Eisenhauer, P.; Manuelyan, I.; Weir, M.E.; Bruce, E.A.; Ballif, B.A.; Botten, J. Host-Driven Phosphorylation Appears to Regulate the Budding Activity of the Lassa Virus Matrix Protein. Pathogens 2018, 7, 97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Zhu, H.; Klemic, J.F.; Chang, S.; Bertone, P.; Casamayor, A.; Klemic, K.G.; Smith, D.; Gerstein, M.; Reed, M.A.; Snyder, M. Analysis of yeast protein kinases using protein chips. Nat. Genet. 2000, 26, 283–289. [Google Scholar] [CrossRef]
  58. Reimer, U.; Reineke, U.; Schneider-Mergener, J. Peptide arrays: From macro to micro. Curr. Opin. Biotechnol. 2002, 13, 315–320. [Google Scholar] [CrossRef]
  59. Zhao, Y.; Jensen, O.N. Modification-specific proteomics: Strategies for characterization of post-translational modifications using enrichment techniques. Proteomics 2009, 9, 4632–4641. [Google Scholar] [CrossRef] [Green Version]
  60. Wu, H.Y.; Lu, C.T.; Kao, H.J.; Chen, Y.J.; Chen, Y.J.; Lee, T.Y. Characterization and identification of protein O-GlcNAcylation sites with substrate specificity. BMC Bioinform. 2014, 15 (Suppl. 16), S1. [Google Scholar] [CrossRef] [Green Version]
  61. Hargett, A.A.; Renfrow, M.B. Glycosylation of viral surface proteins probed by mass spectrometry. Curr. Opin. Virol. 2019, 36, 56–66. [Google Scholar] [CrossRef] [PubMed]
  62. Vigerust, D.J.; Shepherd, V.L. Virus glycosylation: Role in virulence and immune interactions. Trends Microbiol. 2007, 15, 211–218. [Google Scholar] [CrossRef] [PubMed]
  63. Patwardhan, A.; Cheng, N.; Trejo, J. Post-Translational Modifications of G Protein-Coupled Receptors Control Cellular Signaling Dynamics in Space and Time. Pharmacol. Rev. 2021, 73, 120–151. [Google Scholar] [CrossRef] [PubMed]
  64. Piacente, F.; Gaglianone, M.; Laugieri, M.E.; Tonetti, M.G. The Autonomous Glycosylation of Large DNA Viruses. Int. J. Mol. Sci. 2015, 16, 29315–29328. [Google Scholar] [CrossRef] [Green Version]
  65. Varelas, X.; Bouchie, M.P.; Kukuruzinska, M.A. Protein N-glycosylation in oral cancer: Dysregulated cellular networks among DPAGT1, E-cadherin adhesion and canonical Wnt signaling. Glycobiology 2014, 24, 579–591. [Google Scholar] [CrossRef] [Green Version]
  66. Klement, E.; Lipinszki, Z.; Kupihar, Z.; Udvardy, A.; Medzihradszky, K.F. Enrichment of O-GlcNAc modified proteins by the periodate oxidation-hydrazide resin capture approach. J. Proteome Res. 2010, 9, 2200–2206. [Google Scholar] [CrossRef] [Green Version]
  67. Ohyama, Y.; Nakajima, K.; Renfrow, M.B.; Novak, J.; Takahashi, K. Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins. Expert. Rev. Proteom. 2020, 17, 275–296. [Google Scholar] [CrossRef]
  68. Zhao, S.; Walsh, I.; Abrahams, J.L.; Royle, L.; Nguyen-Khuong, T.; Spencer, D.; Fernandes, D.L.; Packer, N.H.; Rudd, P.M.; Campbell, M.P. GlycoStore: A database of retention properties for glycan analysis. Bioinformatics 2018, 34, 3231–3232. [Google Scholar] [CrossRef] [Green Version]
  69. Ke, L.Y.; Chan, H.C.; Chen, C.C.; Lu, J.; Marathe, G.K.; Chu, C.S.; Chan, H.C.; Wang, C.Y.; Tung, Y.C.; McIntyre, T.M.; et al. Enhanced Sphingomyelinase Activity Contributes to the Apoptotic Capacity of Electronegative Low-Density Lipoprotein. J. Med. Chem. 2016, 59, 1032–1040. [Google Scholar] [CrossRef]
  70. Eggink, D.; Melchers, M.; Wuhrer, M.; van Montfort, T.; Dey, A.K.; Naaijkens, B.A.; David, K.B.; Le Douce, V.; Deelder, A.M.; Kang, K.; et al. Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 2010, 401, 236–247. [Google Scholar] [CrossRef] [Green Version]
  71. Tate, M.D.; Job, E.R.; Deng, Y.M.; Gunalan, V.; Maurer-Stroh, S.; Reading, P.C. Playing hide and seek: How glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses 2014, 6, 1294–1316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Thiemmeca, S.; Tamdet, C.; Punyadee, N.; Prommool, T.; Songjaeng, A.; Noisakran, S.; Puttikhunt, C.; Atkinson, J.P.; Diamond, M.S.; Ponlawat, A.; et al. Secreted NS1 Protects Dengue Virus from Mannose-Binding Lectin-Mediated Neutralization. J. Immunol. 2016, 197, 4053–4065. [Google Scholar] [CrossRef] [Green Version]
  73. Ruvoën-Clouet, N.; Mas, E.; Marionneau, S.; Guillon, P.; Lombardo, D.; Le Pendu, J. Bile-salt-stimulated lipase and mucins from milk of ‘secretor’ mothers inhibit the binding of Norwalk virus capsids to their carbohydrate ligands. Biochem. J. 2006, 393 Pt 3, 627–634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Kakakhel, S.; Khan, H.; Nigar, K.; Khan, A. Genomic stratification and differential natural selection signatures among human norovirus genogroup II isolates. Arch. Virol. 2022, 167, 1235–1245. [Google Scholar] [CrossRef] [PubMed]
  75. Nagasawa, K.; Matsushima, Y.; Motoya, T.; Mizukoshi, F.; Ueki, Y.; Sakon, N.; Murakami, K.; Shimizu, T.; Okabe, N.; Nagata, N.; et al. Genetic Analysis of Human Norovirus Strains in Japan in 2016-2017. Front. Microbiol. 2018, 9, 1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Niendorf, S.; Jacobsen, S.; Faber, M.; Eis-Hubinger, A.M.; Hofmann, J.; Zimmermann, O.; Hohne, M.; Bock, C.T. Steep rise in norovirus cases and emergence of a new recombinant strain GII.P16-GII.2, Germany, winter 2016. Euro Surveill. 2017, 22, 30447. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Lu, J.; Fang, L.; Sun, L.; Zeng, H.; Li, Y.; Zheng, H.; Wu, S.; Yang, F.; Song, T.; Lin, J.; et al. Association of GII.P16-GII.2 Recombinant Norovirus Strain with Increased Norovirus Outbreaks, Guangdong, China, 2016. Emerg. Infect. Dis. 2017, 23, 1188–1190. [Google Scholar] [CrossRef] [Green Version]
  78. Kokkinidis, M.; Glykos, N.M.; Fadouloglou, V.E. Catalytic activity regulation through post-translational modification: The expanding universe of protein diversity. Adv. Protein Chem. Struct. Biol. 2020, 122, 97–125. [Google Scholar]
  79. Singh, B.K.; Leuthold, M.M.; Hansman, G.S. Human noroviruses’ fondness for histo-blood group antigens. J. Virol. 2015, 89, 2024–2040. [Google Scholar] [CrossRef] [Green Version]
  80. Graziano, V.R.; Wei, J.; Wilen, C.B. Norovirus Attachment and Entry. Viruses 2019, 11, 495. [Google Scholar] [CrossRef] [Green Version]
  81. Hassan, E.; Baldridge, M.T. Norovirus encounters in the gut: Multifaceted interactions and disease outcomes. Mucosal Immunol. 2019, 12, 1259–1267. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Yang, X.; Qian, K. Protein O-GlcNAcylation: Emerging mechanisms and functions. Nat. Rev. Mol. Cell. Biol. 2017, 18, 452–465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. van der Laarse, S.A.M.; Leney, A.C.; Heck, A.J.R. Crosstalk between phosphorylation and O-GlcNAcylation: Friend or foe. FEBS J. 2018, 285, 3152–3167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Nie, H.; Yi, W. O-GlcNAcylation, a sweet link to the pathology of diseases. J. Zhejiang Univ. Sci. B 2019, 20, 437–448. [Google Scholar] [CrossRef]
  85. Hart, G.W.; Slawson, C.; Ramirez-Correa, G.; Lagerlof, O. Cross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 2011, 80, 825–858. [Google Scholar] [CrossRef] [Green Version]
  86. Steentoft, C.; Vakhrushev, S.Y.; Joshi, H.J.; Kong, Y.; Vester-Christensen, M.B.; Schjoldager, K.T.; Lavrsen, K.; Dabelsteen, S.; Pedersen, N.B.; Marcos-Silva, L.; et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. Embo J. 2013, 32, 1478–1488. [Google Scholar] [CrossRef] [Green Version]
  87. Vercoutter-Edouart, A.S.; El Yazidi-Belkoura, I.; Guinez, C.; Baldini, S.; Leturcq, M.; Mortuaire, M.; Mir, A.M.; Steenackers, A.; Dehennaut, V.; Pierce, A.; et al. Detection and identification of O-GlcNAcylated proteins by proteomic approaches. Proteomics 2015, 15, 1039–1050. [Google Scholar] [CrossRef]
  88. Huang, J.; Wang, F.; Ye, M.; Zou, H. Enrichment and separation techniques for large-scale proteomics analysis of the protein post-translational modifications. J. Chromatogr. A 2014, 1372c, 1–17. [Google Scholar] [CrossRef]
  89. Butkinaree, C.; Park, K.; Hart, G.W. O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim. Biophys. Acta 2010, 1800, 96–106. [Google Scholar] [CrossRef] [Green Version]
  90. Huang, B.; Liu, Y.; Yao, H.; Zhao, Y. NMR-based investigation into protein phosphorylation. Int. J. Biol. Macromol. 2020, 145, 53–63. [Google Scholar] [CrossRef]
  91. Han, S.H.; Kim, S.J.; Kim, E.J.; Kim, T.E.; Moon, J.S.; Kim, G.W.; Lee, S.H.; Cho, K.; Yoo, J.S.; Son, W.S.; et al. Phosphorylation of hepatitis C virus RNA polymerases ser29 and ser42 by protein kinase C-related kinase 2 regulates viral RNA replication. J. Virol. 2014, 88, 11240–11252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Riley, N.M.; Bertozzi, C.R.; Pitteri, S.J. A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry-Based Glycoproteomics. Mol. Cell. Proteom. 2021, 20, 100029. [Google Scholar] [CrossRef] [PubMed]
  93. Zhao, Y.; Muir, T.W.; Kent, S.B.; Tischer, E.; Scardina, J.M.; Chait, B.T. Mapping protein-protein interactions by affinity-directed mass spectrometry. Proc. Natl. Acad. Sci. USA 1996, 93, 4020–4024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. McLachlin, D.T.; Chait, B.T. Analysis of phosphorylated proteins and peptides by mass spectrometry. Curr. Opin. Chem. Biol. 2001, 5, 591–602. [Google Scholar] [CrossRef] [PubMed]
  95. Thingholm, T.E.; Jorgensen, T.J.; Jensen, O.N.; Larsen, M.R. Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 2006, 1, 1929–1935. [Google Scholar] [CrossRef]
  96. Kim, S.J.; Kim, J.H.; Kim, Y.G.; Lim, H.S.; Oh, J.W. Protein kinase C-related kinase 2 regulates hepatitis C virus RNA polymerase function by phosphorylation. J. Biol. Chem. 2004, 279, 50031–50041. [Google Scholar] [CrossRef] [Green Version]
  97. Ahlquist, P.; Noueiry, A.O.; Lee, W.M.; Kushner, D.B.; Dye, B.T. Host factors in positive-strand RNA virus genome replication. J. Virol. 2003, 77, 8181–8186. [Google Scholar] [CrossRef] [Green Version]
  98. Jakubiec, A.; Tournier, V.; Drugeon, G.; Pflieger, S.; Camborde, L.; Vinh, J.; Héricourt, F.; Redeker, V.; Jupin, I. Phosphorylation of viral RNA-dependent RNA polymerase and its role in replication of a plus-strand RNA virus. J. Biol. Chem. 2006, 281, 21236–21249. [Google Scholar] [CrossRef] [Green Version]
  99. Goodfellow, I. The genome-linked protein VPg of vertebrate viruses—a multifaceted protein. Curr. Opin. Virol. 2011, 1, 355–362. [Google Scholar] [CrossRef] [Green Version]
Viruses 15 00798 g002 550
Figure 2. Replication cycle of noroviruses and post-translational modification crosstalk between phosphorylation and O-GlcNAcylation. Co-occurring PTMs on proteins are common, and PTM crosstalk between phosphorylation and O-GlcNAcylation is the most common since they will compete for the same residues (serine/threonine residues). Phosphorylation is required for viral function. In contrast, O-GlcNAcylation of norovirus capsid protein VP1 could interfere with receptor binding. Studies on the O-GlcNAcylation of noroviruses are few and lack direct evidence from receptor binding assays. Abbreviations: HBGA, histo-blood group antigen; VP1, major capsid protein VP1; ATP, adenosine triphosphate; ADP, adenosine diphosphate; OGT, O-linked N-acetylglucosamine (GlcNAc) transferase; OGA, O-GlcNAcase; O-GlcNAc, O-linked N-acetylglucosamine; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine.
Figure 2. Replication cycle of noroviruses and post-translational modification crosstalk between phosphorylation and O-GlcNAcylation. Co-occurring PTMs on proteins are common, and PTM crosstalk between phosphorylation and O-GlcNAcylation is the most common since they will compete for the same residues (serine/threonine residues). Phosphorylation is required for viral function. In contrast, O-GlcNAcylation of norovirus capsid protein VP1 could interfere with receptor binding. Studies on the O-GlcNAcylation of noroviruses are few and lack direct evidence from receptor binding assays. Abbreviations: HBGA, histo-blood group antigen; VP1, major capsid protein VP1; ATP, adenosine triphosphate; ADP, adenosine diphosphate; OGT, O-linked N-acetylglucosamine (GlcNAc) transferase; OGA, O-GlcNAcase; O-GlcNAc, O-linked N-acetylglucosamine; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine.
Viruses 15 00798 g002
Viruses 15 00798 g003 550
Figure 3. PTM crosstalk between O-GlcNAcylation and phosphorylation. Phosphorylation occurs when protein kinase attaches a phosphate group from ATP to the substrate; in contrast, PPase removes a phosphate group from a phosphoprotein. Similarly, OGT adds O-GlcNAc from UDP-GlcNAc to the substrates for O-GlcNAcylation. Conversely, OGA removes O-GlcNAc. These two processes are both reversible. Because phosphorylation and O-GlcNAcylation can compete for serine and threonine residues, PTM crosstalk occurs [83]. Abbreviations: O-GlcNAc, O-linked β-N-acetylglucosamine; OGT, O-GlcNAc transferase; OGA, O-GlcNAcase; Ser, serine; Thr, threonine; ATP, adenosine triphosphate; ADT, adenosine diphosphate; UPD, uridine diphosphate; PPase, protein phosphatase.
Figure 3. PTM crosstalk between O-GlcNAcylation and phosphorylation. Phosphorylation occurs when protein kinase attaches a phosphate group from ATP to the substrate; in contrast, PPase removes a phosphate group from a phosphoprotein. Similarly, OGT adds O-GlcNAc from UDP-GlcNAc to the substrates for O-GlcNAcylation. Conversely, OGA removes O-GlcNAc. These two processes are both reversible. Because phosphorylation and O-GlcNAcylation can compete for serine and threonine residues, PTM crosstalk occurs [83]. Abbreviations: O-GlcNAc, O-linked β-N-acetylglucosamine; OGT, O-GlcNAc transferase; OGA, O-GlcNAcase; Ser, serine; Thr, threonine; ATP, adenosine triphosphate; ADT, adenosine diphosphate; UPD, uridine diphosphate; PPase, protein phosphatase.
Viruses 15 00798 g003
Table
Table 1. Established roles of N- and O-glycosylation, O-GlcNAcylation, and phosphorylation in viral pathogenesis.
Table 1. Established roles of N- and O-glycosylation, O-GlcNAcylation, and phosphorylation in viral pathogenesis.
PTMEffectVirusMethodYearReference
N- and O-glycosylationAttachment and entryN-glycosylation: Ebola, HIV-1;
N- and O-glycosylation: SARS-CoV2		PNGase F, Endo HF,
HILIC-UPLC, MALDI TOF		2009, 2010, 2010, 2022[32,33,34,35]
Viral replication and maturationN-glycosylation: influenza, DENV, rotavirus;
N- and O-glycosylation: SARS-CoV2		PNGase F, Western blot, HILIC-UPLC, MALDI TOF2022, 1999
2017, 2023		[35,36,37,38]
Viral pathologyN-glycosylation: DENV, influenza, ZIKVPNGase F, Western blot,
lectins		1999, 2017
2023		[36,37,39]
Immune evasion by glycan shieldingN-glycosylation: Ebola, influenza, coronavirus, HIV-1, arenavirus, SARS-CoV2PNGase F,
Western blot,
Synapt G2S, Orbitrap MS, HILIC-UPLC		2009, 2017
2020, 2016
2015, 2022
2022		[32,37,40,41,42,43,44]
Release of new virus particlesN-glycosylation: influenza;
N- and O-glycosylation: SARS-CoV2		PNGase F,
LC-MS		2022
1999		[35,45]
O-GlcNAcylationAttachment and entry into cellsNorovirusLectins,
antibodies,
GC-MS		2022[46]
RNA polymerase II transcription factorsRotavirusEnzyme1991[47]
Viral protein stabilityAdenovirus, baculovirusWGA, [14C] GlcN radiolabeled fiber1992
1989		[48,49]
Viral pathologyHuman cytomegalovirusElectrospray-MS1994[50]
PhosphorylationViral replication and maturationAlphavirus, Ebola, HCVAntibodies,
Western blot 		2022, 2018
2019		[51,52,53]
Viral protein synthesisNorovirus, FCVElectrophoresis2016, 2011[15,16]
Inhibition of immune pathwaysDENV, ZIKV, yellow fever virus, SARS-CoVMetabolic labeling
immunoblot 		2005
2009		[54,55]
Release of new virus particlesLassa virusGel electrophoresis
LC-MS/MS		2018[56]
Effects of the three types of PTMs. Abbreviations: PTMs, post-translational modifications; HIV-1, human immunodeficiency virus-1; DENV, dengue virus; ZIKV, Zika virus; HCV, hepatitis C virus; FCV, feline calicivirus; SARS-CoV, severe acute respiratory syndrome-associated coronavirus; PNGase F, peptide-N-glycosidase F; Endo HF, endo-β-N-acetylglucosaminidase H; HILIC, hydrophilic interaction liquid chromatography; UPLC, ultraperformance liquid chromatography; MS, mass spectrometry; GC, gas chromatography; MALDI TOF, matrix-assisted laser desorption/ionization-time of flight; SYNAPT G2S high definition mass spectrometer (HDMS) is used for discovery and targeted omic-based experiments; Orbitrap MS, ion trap high-resolution mass spectrometry analyzer; WGA, wheat germ agglutinin; GalNAc, N-acetyl-P-D-galactosamine; MS, mass spectrometry.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Cheng, C.-C.; Ke, G.-M.; Chu, P.-Y.; Ke, L.-Y. Elucidating the Implications of Norovirus N- and O-Glycosylation, O-GlcNAcylation, and Phosphorylation. Viruses 2023, 15, 798. https://doi.org/10.3390/v15030798

AMA Style

Cheng C-C, Ke G-M, Chu P-Y, Ke L-Y. Elucidating the Implications of Norovirus N- and O-Glycosylation, O-GlcNAcylation, and Phosphorylation. Viruses. 2023; 15(3):798. https://doi.org/10.3390/v15030798

Chicago/Turabian Style

Cheng, Chia-Chi, Guan-Ming Ke, Pei-Yu Chu, and Liang-Yin Ke. 2023. "Elucidating the Implications of Norovirus N- and O-Glycosylation, O-GlcNAcylation, and Phosphorylation" Viruses 15, no. 3: 798. https://doi.org/10.3390/v15030798

APA Style

Cheng, C. -C., Ke, G. -M., Chu, P. -Y., & Ke, L. -Y. (2023). Elucidating the Implications of Norovirus N- and O-Glycosylation, O-GlcNAcylation, and Phosphorylation. Viruses, 15(3), 798. https://doi.org/10.3390/v15030798

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop